Would you recommend adding 4c of adjuvant nivolumab following SBRT to oligorecurrent NSCLC extrapolating from I-SABR results?
This question is part of our ASTRO 2026 collaboration, inspired by the Clinical Trials Session Presentation "6-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial" by Dr. Joe Chang, MD, PhD, MS, FASTRO
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · University of Texas MD Anderson Cancer Center
Answered on
Extrapolating I-SABR results to oligo-recurrent NSCLC needs further investigation. Some preliminary prospective randomized studies have indicated that SBRT with concurrent IO may be beneficial for treatment-naive oligo-metastatic NSCLC or oligo-progressive disease after systemic therapy, including I...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · LSU Health Sciences Center
Answered on
Oligorecurrent NSCLC appropriately salvaged with SBRT may or may not need adjuvant systemic therapy. I would weigh several factors when discussing the need for systemic therapy with the medical oncology team: how long the patient has been off systemic therapy, their performance status/quality of lif...
Join for free or sign in to see the full answer